Abstract:Background COVID-19 is a new and highly contagious respiratory disease that has caused global spread, high case fatality rate in severe patients, and a huge medical burden due to invasive mechanical ventilation. The current diagnosis and treatment guidelines are still need to be improved, and more excellent clinical experience is needed to provide reference. Methods We analyzed and summarized clinical data of 97 confirmed COVID-19 adult patients (including 26 severe cases) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 17, 2020 to March 10, 2020, included laboratory examination results, imaging findings, treatment effect, prognosis, etc, in order to put forward prediction index of severe COVID-19 patients, principles of early intervention and methylprednisolone usages in COVID-19 patients. Results 1. Hypoxemia, hyperlactic acid, hypoproteinemia, and hypokalemia were prevalent in COVID-19 patients. The significant low lymphocyte count, hypoproteinemia, hypokalemia, the persistent or worsen high CRP, high D-dimer, and high BNP, and the occurrence of hemoptysis and novel coronavirus (SARS-CoV-2) viremia were important indicators for early diagnosis and prediction of severe disease progression. 2. Characteristic images of lung CT had a clear change in COVID-19, Ground-glass opacity (GGO) and high-density linear combinations may indicate different pathological changes. Rapid lobular progression of GGO suggests the possibility of severe disease. 3. Basic principles of early intervention treatment of COVID-19: on the premise of no effective antiviral drugs, treatment is based on supportive and symptomatic therapy (albumin supplementation, supplement of potassium, supplement blood plasma, etc.) in order to maintain the stability of the intracellular environment and adequately reactivate body immunity to clean up SARS-CoV-2. 4. According to severity, oxygenation index, body weight, age, underlying diseases, appropriate amount methylprednisolone application on severe/critical COVID-19 patients on demand, improved blood oxygen and reduced the utilization rate of invasive mechanical ventilation, case fatality rate and medical burden significantly. The most common indications for invasive mechanical ventilation should be strictly control in critical COVID-19 patients. Conclusions 1. Accurate and timely identification of clinical features in severe risks, and early and appropriate intervention can block disease progression. 2. Appropriate dose of methylprednisolone can effectively avoid invasive mechanical ventilation and reduce case fatality rate in critical COVID-19 patients. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial This study is a retrospective observational study, so we do not need a trial ID ### Funding Statement NO funding ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The readers can access the data supporting the conclusions of the study in the manuscript and updated manuscript if the data has been updated

Targeted lipidomics data of COVID-19 patients

The Serum Metabolome of COVID-19 Patients is Distinctive and Predictive

Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Dissecting lipid metabolism alterations in SARS-CoV-2

Deep phenotyping of the lipidomic response in COVID-19 and non-COVID-19 sepsis

A comprehensive IDA and SWATH-DIA Lipidomics and Metabolomics dataset: SARS-CoV-2 case control study

Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

Lipidome is a Valuable Tool for the Severity Prediction of Coronavirus Disease 2019

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

Key to successful treatment of COVID 19: accurate identification of severe risks and early intervention of disease progression

Sulfated Bile Acids in Serum as Potential Biomarkers of Disease Severity and Mortality in COVID-19

Quantitative LC-MS study of compounds found predictive of COVID-19 severity and outcome

Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts

Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment

Lipidomics signature in post-COVID patient sera and its influence on the prolonged inflammatory response

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis

Systematic Discovery and Pathway Analyses of Metabolic Disturbance in COVID-19

Proteomic blood profiling in mild, severe and critical COVID-19 patients